ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Petersen LR, Stramer SL, Powers AM, 2010. Chikungunya virus: possible impact on transfusion medicine. Transfus Med Rev 24: 15–21.
-
2.
Centers for Disease Control and Prevention, 2012. West Nile Virus (WNV) Human Infections Reported to ArboNET by State, United States, 2012 (as of September 18, 2012). Available at: http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount12_detailed.htm. Accessed September 20, 2012.
-
3.
Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, Bedno S, Burke H, Dumilla AM, Konde J, Njenga MK, Sang R, Breiman RF, 2008. Seroprevalence of chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am J Trop Med Hyg 78: 333–337.
-
4.
Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, Kelly CH, Sang R, Sergon K, Breiman R, Powers AM, 2008. Tracking epidemic chikungunya virus into the Indian Ocean from East Africa. J Gen Virol 89: 2754–2760.
-
5.
Sergon K, Yahaya AA, Brown J, Bedja SA, Mlindasse M, Agata N, Allaranger Y, Ball MD, Powers AM, Ofula V, Onyango C, Konongoi LS, Sang R, Njenga MK, Breiman RF, 2007. Seroprevalence of chikungunya virus infection on Grande Comore Island, Union of the Comoros, 2005. Am J Trop Med Hyg 76: 1189–1193.
-
6.
Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney MC, Lavenir R, Pardigon N, Reynes JM, Pettinelli F, Biscornet L, Diancourt L, Michel S, Duquerroy S, Guigon G, Frenkiel MP, Brehin AC, Cubito N, Despres P, Kunst F, Rey FA, Zeller H, Brisse S, 2006. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 3: e263.
-
7.
International Society for Infectious Diseases, 2010. CHIKUNGUNYA, (04): MADAGASCAR (FIANARANTSOA). Archive number 2010026.0639. Available at: http://www.promedmail.org. Accessed September 25, 2012.
-
8.
Kularatne SA, Gihan MC, Weerasinghe SC, Gunasena S, 2009. Concurrent outbreaks of chikungunya and dengue fever in Kandy, Sri Lanka, 2006–07: a comparative analysis of clinical and laboratory features. Postgrad Med J 85: 342–346.
-
9.
Yoosuf AA, Shiham I, Mohamed AJ, Ali G, Luna JM, Pandav R, Gongal GN, Nisaluk A, Jarman RG, Gibbons RV, 2009. First report of chikungunya from the Maldives. Trans R Soc Trop Med Hyg 103: 192–196.
-
10.
Sam IC, Chan YF, Chan SY, Loong SK, Chin HK, Hooi PS, Ganeswrie R, Abubakar S, 2009. Chikungunya virus of Asian and Central/East African genotypes in Malaysia. J Clin Virol 46: 180–183.
-
11.
AbuBakar S, Sam IC, Wong PF, MatRahim N, Hooi PS, Roslan N, 2007. Reemergence of endemic chikungunya, Malaysia. Emerg Infect Dis 13: 147–149.
-
12.
Ng LC, Tan LK, Tan CH, Tan SS, Hapuarachchi HC, Pok KY, Lai YL, Lam-Phua SG, Bucht G, Lin RT, Leo YS, Tan BH, Han HK, Ooi PL, James L, Khoo SP, 2009. Entomologic and virologic investigation of chikungunya, Singapore. Emerg Infect Dis 15: 1243–1249.
-
13.
Rianthavorn P, Prianantathavorn K, Wuttirattanakowit N, Theamboonlers A, Poovorawan Y, 2010. An outbreak of chikungunya in southern Thailand from 2008 to 2009 caused by African strains with A226V mutation. Int J Infect Dis 14 (Suppl 3): e161–e165.
-
14.
Yergolkar PN, Tandale BV, Arankalle VA, Sathe PS, Sudeep AB, Gandhe SS, Gokhle MD, Jacob GP, Hundekar SL, Mishra AC, 2006. Chikungunya outbreaks caused by African genotype, India. Emerg Infect Dis 12: 1580–1583.
-
15.
International Society for Infectious Diseases, 2010. CHIKUNGUNYA, (30) CHINA (GUANGDONG), REUNION. Archive number 20101008.3661. Available at: http://www.promedmail.org. Accessed September 25, 2012.
-
16.
Angelini R, Finarelli AC, Angelini P, Po C, Petropulacos K, Silvi G, Macini P, Fortuna C, Venturi G, Magurano F, Fiorentini C, Marchi A, Benedetti E, Bucci P, Boros S, Romi R, Majori G, Ciufolini MG, Nicoletti L, Rezza G, Cassone A, 2007. Chikungunya in north-eastern Italy: a summing up of the outbreak. Euro Surveill 12: E071122.2.
-
17.
Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, Cordioli P, Fortuna C, Boros S, Magurano F, Silvi G, Angelini P, Dottori M, Ciufolini MG, Majori GC, Cassone A, 2007. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370: 1840–1846.
-
18.
Grandadam M, Caro V, Plumet S, Thiberge JM, Souares Y, Failloux AB, Tolou HJ, Budelot M, Cosserat D, Leparc-Goffart I, Despres P, 2011. Chikungunya virus, southeastern France. Emerg Infect Dis 17: 910–913.
-
19.
Schwartz O, Albert ML, 2010. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol 8: 491–500.
-
20.
Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV, 2008. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg Infect Dis 14: 412–415.
-
21.
Casolari S, Briganti E, Zanotti M, Zauli T, Nicoletti L, Magurano F, Fortuna C, Fiorentini C, Grazia Ciufolini M, Rezza G, 2008. A fatal case of encephalitis associated with chikungunya virus infection. Scand J Infect Dis 40: 995–996.
-
22.
Ganesan K, Diwan A, Shankar SK, Desai SB, Sainani GS, Katrak SM, 2008. Chikungunya encephalomyeloradiculitis: report of 2 cases with neuroimaging and 1 case with autopsy findings. AJNR Am J Neuroradiol 29: 1636–1637.
-
23.
Josseran L, Paquet C, Zehgnoun A, Caillere N, Le Tertre A, Solet JL, Ledrans M, 2006. Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 12: 1994–1995.
-
24.
Ramchurn SK, Goorah SS, Makhan M, Moheeput K, 2008. Excess mortality as an epidemic intelligence tool in chikungunya mapping. Euro Surveill 13: 8039.
-
25.
Tandale BV, Sathe PS, Arankalle VA, Wadia RS, Kulkarni R, Shah SV, Shah SK, Sheth JK, Sudeep AB, Tripathy AS, Mishra AC, 2009. Systemic involvements and fatalities during chikungunya epidemic in India, 2006. J Clin Virol 46: 145–149.
-
26.
Powers AM, Logue CH, 2007. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 88: 2363–2377.
-
27.
Jupp PG, McIntosh BM, 1988. Chikungunya virus disease. Monath TP, ed. The Arboviruses: Epidemiology and Ecology. Boca Raton, FL: CRC Press, 137–157.
-
28.
Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S, 2007. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 3: e201.
-
29.
Tsetsarkin KA, Chen R, Leal G, Forrester N, Higgs S, Huang J, Weaver SC, 2011. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc Natl Acad Sci USA 108: 7872–7877.
-
30.
Benedict MQ, Levine RS, Hawley WA, Lounibos LP, 2007. Spread of the tiger: global risk of invasion by the mosquito Aedes albopictus. Vector Borne Zoonotic Dis 7: 76–85.
-
31.
Liumbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C, Macini P, Tomasini I, Zucchelli P, Silvestri AR, Sambri V, Pupella S, Catalano L, Piccinini V, Calizzani G, Grazzini G, 2008. The chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 6: 199–210.
-
32.
Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP, 2009. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de La Reunion. Transfusion 49: 1083–1091.
-
33.
Brouard C, Bernillon P, Quatresous I, Pillonel J, Assal A, De Valk H, Desenclos JC, 2008. Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 48: 1333–1341.
-
34.
Sissoko D, Moendandze A, Malvy D, Giry C, Ezzedine K, Solet JL, Pierre V, 2008. Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005–2006: a population-based survey. PLoS ONE 3: e3066.
-
35.
Queyriaux B, Simon F, Grandadam M, Michel R, Tolou H, Boutin JP, 2008. Clinical burden of chikungunya virus infection. Lancet Infect Dis 8: 2–3.
-
36.
Appassakij H, Khuntikij P, Kemapunmanus M, Wutthanarungsan R, Silpapojakul K, 2012. Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? Transfusion 26: [Epub ahead of print], doi:10.1111/j.1537-2995.2012.03960.x.
-
37.
Gerardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, Michault A, de Lamballerie X, Flahault A, Favier F, 2008. Estimating chikungunya prevalence in La Reunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC Infect Dis 8: 99.
-
38.
Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L, 2005. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 45: 580–590.
-
39.
Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K, 2003. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 47: 475–479.
-
40.
Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, Corash L, 2006. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46: 1168–1177.
-
41.
Lin L, Dikeman R, Molini B, Lukehart S, Lane R, Dupuis K, Metzel P, Corash L, 2004. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 44: 1496–1504.
-
42.
Grellier P, Benach J, Labaied M, Cahrneau S, Gil H, Monsalve G, Alfonso R, Sawyer L, Lin L, Steiert M, Dupuis K, 2008. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 48: 1676–1684.
-
43.
Sawyer L, Hanson D, Castro G, Luckett W, Dubensky TW, Stassinopoulos A, 2007. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 47: 1062–1070.
-
44.
Grass JA, Hei DJ, Metchette K, Cimino GD, Weisenhahn GP, Corash L, Lin L, 1998. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 91: 2180.
-
45.
Eastman RT, Barrett LK, Dupuis K, Buckner FS, Van Voorhis WC, 2005. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 45: 1459–1463.
-
46.
Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman J, Isaacs ST, Wollowitz S, Corash L, 1997. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37: 423–435.
-
47.
Wollowitz S, 2001. Fundamentals of the psoralen-based helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 38 (Suppl 11): 4–11.
-
48.
Irsch J, Pinkoski L, Corash L, Lin L, 2010. INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis. Vox Sang 98: 47–55.
-
49.
Lin L, Alfonso R, Behrman B, Corten L, Damonte PB, Dikeman R, Dupuis K, Hei D, Lin CY, Londe HF, Metchette K, Phan T, Reames AA, Rheinschmidt M, Savoor A, Tessman J, Corash L, 1998. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Infusther Tranfsusmed 25: 39–48.
-
50.
McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard FT, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG, 2004. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 104: 1534–1541.
-
51.
de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L, 2005. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 45: 1362–1372.
-
52.
van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L, 2003. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 101: 2426–2433.
-
53.
Lin L, Conlan MG, Tessman J, Cimino G, Porter S, 2005. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 45: 1610–1620.
-
54.
ANSM, 2013. French Agency for the Safety of Health Products. France Annual Haemovigilance report 2009. Available at: http://www.ansm.sante.fr/Mediatheque/Publications/Information-in-English. Accessed September 20, 2012.
-
55.
Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, Raidot JP, Kandel G, Wiesel ML, Corash L, 2011. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 51: 622–629.
-
56.
Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L, 2008. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 94: 315–323.
-
57.
Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L, 2009. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 49: 1412–1422.
-
58.
Devine DV, Sher GD, Reesink HW, Panzer S, Hetzel PA, Wong JK, Horvath M, Leitner GC, Schennach H, Nussbaumer W, Genoe K, Cioffi JM, Givisiez FN, Rogerson M, Howe D, Delage G, Sarappa C, Charbonneau, Fu Y, Sarlija D, Vuk T, Strauss Patko M, Balija M, Jukic I, Ali A, Auvinen MK, Jaakonsalo E, Cazenave JP, Waller C, Kientz D, David B, Walther-Wenke G, Heiden M, Lin CK, Tsoi WC, Lee CK, Barotine-Toth K, Sawant RB, Murphy W, Quirke B, Bowler P, Shinar E, Yahalom V, Aprili G, Piccoli P, Gandini G, Tadokaro K, Nadarajan VS, de Kort W, Jansen N, Flanagan P, Forsberg PO, Hervig T, Letowska M, Lachert E, Dudziak K, Antoniewicz-Papis J, de Olim G, Nascimento F, Hindawi S, Teo D, Reddy R, Scholtz J, Swanevelder R, Rovira LP, Sauleda S, Carasa MA, Vaquero MP, Ania MA, Gulliksson H, Holdsworth S, Cotton S, Howell C, Baldwin C, Cusick RM, Geele GA, Paden C, McEvoy P, Gottschall JL, McLaughlin LS, Benjamin RJ, Eder A, Draper NL, AuBuchon JP, Leon de Gonzalez G, 2010. Inventory management. Vox Sang 98: e295–e363.
-
59.
Reed LJ, Muench H, 1938. A simple method for estimating fifty per cent endpoints. Am J Hyg 27: 493–497.
-
60.
Vanlandingham DL, Keil SD, McElroy Horne K, Pyles R, Goodrich RP, Higgs S, 2012. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 53: 284–290.
-
61.
Leo YS, Chow ALP, Tan LK, Lye DC, Lin L, Ng LC, 2009. Chikungunya outbreak, Singapore 2008. Emerg Infect Dis 15: 836–837.
-
62.
Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Schwartz O, 2007. Characterization of reemerging chikungunya virus. PLoS Pathog 3: e89.
-
63.
McIntosh BM, Paterson HE, Donaldson JM, de Sousa J, 1963. Chikungunya virus: viral susceptibility and transmission studies with some vertebrates. S Afr J Med Sci 28: 45.
-
64.
Chemsky MA, Larke RP, 1977. Contrasting effects of rabbit and human platelets on chikungunya virus infectivity. Can J Microbiol 23: 1237–1244.
-
65.
Larke RP, Wheelock EF, 1970. Stabilization of chikungunya virus infectivity by human blood platelets. J Infect Dis 122: 523–531.
-
66.
Parola P, de Lamballerie X, Jourdan J, Rovery C, Vaillant V, Minodier P, Brouqui P, Flahault A, Raoult D, Charrel RN, 2006. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 12: 1493–1499.
-
67.
Carletti F, Bordi L, Chiappini R, Ippolito G, Sciarrone MR, Capobianchi MR, Di Caro A, Castilletti C, 2007. Rapid detection and quantification of chikungunya virus by a one-step reverse transcription polymerase chain reaction real-time assay. Am J Trop Med Hyg 77: 521–524.
-
68.
Tomson B, Brand A, 2010. In vivo tracking of transfused platelets for recovery and survival studies: an appraisal of labeling methods. Transfus Apheresis Sci 42: 53–61.
-
69.
Custer B, Agapova M, Martinez RH, 2010. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 50: 2461–2473.
-
70.
INTERCEPT In Use, 2012. Intercept Blood System. Available at: www.interceptbloodsystem.com/intercept-in-use/overview.html. Accessed December 15, 2012.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 608 | 488 | 33 |
| Full Text Views | 657 | 5 | 0 |
| PDF Downloads | 77 | 10 | 0 |
Photochemical Inactivation of Chikungunya Virus in Human Apheresis Platelet Components by Amotosalen and UVA Light
Konstantin A. Tsetsarkin
Konstantin A. Tsetsarkin
Department of Pathology, University of Texas Medical Branch, Galveston, Texas; Cerus Corporation, Concord, California; Biosecurity Research Institute, Kansas State University, Manhattan, Kansas
Search for other papers by Konstantin A. Tsetsarkin in
Current site
Google Scholar
PubMed
Search for other papers by Konstantin A. Tsetsarkin in
Current site
Google Scholar
PubMed
Adam Sampson-Johannes
Adam Sampson-Johannes
Department of Pathology, University of Texas Medical Branch, Galveston, Texas; Cerus Corporation, Concord, California; Biosecurity Research Institute, Kansas State University, Manhattan, Kansas
Search for other papers by Adam Sampson-Johannes in
Current site
Google Scholar
PubMed
Search for other papers by Adam Sampson-Johannes in
Current site
Google Scholar
PubMed
Lynette Sawyer
Lynette Sawyer
Department of Pathology, University of Texas Medical Branch, Galveston, Texas; Cerus Corporation, Concord, California; Biosecurity Research Institute, Kansas State University, Manhattan, Kansas
Search for other papers by Lynette Sawyer in
Current site
Google Scholar
PubMed
Search for other papers by Lynette Sawyer in
Current site
Google Scholar
PubMed
John Kinsey
John Kinsey
Department of Pathology, University of Texas Medical Branch, Galveston, Texas; Cerus Corporation, Concord, California; Biosecurity Research Institute, Kansas State University, Manhattan, Kansas
Search for other papers by John Kinsey in
Current site
Google Scholar
PubMed
Search for other papers by John Kinsey in
Current site
Google Scholar
PubMed
Stephen Higgs
Stephen Higgs
Department of Pathology, University of Texas Medical Branch, Galveston, Texas; Cerus Corporation, Concord, California; Biosecurity Research Institute, Kansas State University, Manhattan, Kansas
Search for other papers by Stephen Higgs in
Current site
Google Scholar
PubMed
Search for other papers by Stephen Higgs in
Current site
Google Scholar
PubMed
Dana L. Vanlandingham
Dana L. Vanlandingham
Department of Pathology, University of Texas Medical Branch, Galveston, Texas; Cerus Corporation, Concord, California; Biosecurity Research Institute, Kansas State University, Manhattan, Kansas
Search for other papers by Dana L. Vanlandingham in
Current site
Google Scholar
PubMed
Search for other papers by Dana L. Vanlandingham in
Current site
Google Scholar
PubMed
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that recently re-emerged in Africa and rapidly spread into countries of the Indian Ocean basin and South-East Asia. The mean viremic blood donation risk for CHIKV on La Réunion reached 1.5% at the height of the 2005–2006 outbreaks, highlighting the need for development of safety measures to prevent transfusion-transmitted infections. We describe successful inactivation of CHIKV in human platelets and plasma using photochemical treatment with amotosalen and long wavelength UVA illumination. Platelet components in additive solution and plasma units were inoculated with two different strains of high titer CHIKV stock (6.0–8.0 logs/mL), and then treated with amotosalen and exposure to 1.0–3.0 J/cm2 UVA. Based on in vitro assays of infectious virus pre- and post-treatment to identify endpoint dilutions where virus was not detectable, mean viral titers could effectively be reduced by > 6.4 ± 0.6 log10 TCID50/mL in platelets and ≥ 7.6 ± 1.4 logs in plasma, indicating this treatment has the capacity to prevent CHIKV transmission in human blood components collected from infected donors in or traveling from areas of CHIKV transmission.
Author Notes
Financial support: Funding for this study was provided by Cerus Corporation.
Authors' addresses: Konstantin A. Tsetsarkin, National Institutes of Allergy and Infectious Diseases, Neurotropic Flaviviruses Section, Bethesda, MD, E-mail: tsetsarkinka@niaid.nih.gov. Adam Sampson-Johannes, Lynette Sawyer, and John Kinsey, Cerus Corporation, Concord, CA, E-mails: Dna.3@sbcglobal.net, LSawyer@cerus.com, and shotokando@aol.com. Stephen Higgs, Biosecurity Research Institute, Kansas State University, Manhattan, KS, E-mail: shiggs@k-state.edu. Dana L. Vanlandingham, Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, E-mail: dlvanlan@vet.k-state.edu.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Petersen LR, Stramer SL, Powers AM, 2010. Chikungunya virus: possible impact on transfusion medicine. Transfus Med Rev 24: 15–21.
-
2.
Centers for Disease Control and Prevention, 2012. West Nile Virus (WNV) Human Infections Reported to ArboNET by State, United States, 2012 (as of September 18, 2012). Available at: http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount12_detailed.htm. Accessed September 20, 2012.
-
3.
Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, Bedno S, Burke H, Dumilla AM, Konde J, Njenga MK, Sang R, Breiman RF, 2008. Seroprevalence of chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am J Trop Med Hyg 78: 333–337.
-
4.
Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, Kelly CH, Sang R, Sergon K, Breiman R, Powers AM, 2008. Tracking epidemic chikungunya virus into the Indian Ocean from East Africa. J Gen Virol 89: 2754–2760.
-
5.
Sergon K, Yahaya AA, Brown J, Bedja SA, Mlindasse M, Agata N, Allaranger Y, Ball MD, Powers AM, Ofula V, Onyango C, Konongoi LS, Sang R, Njenga MK, Breiman RF, 2007. Seroprevalence of chikungunya virus infection on Grande Comore Island, Union of the Comoros, 2005. Am J Trop Med Hyg 76: 1189–1193.
-
6.
Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney MC, Lavenir R, Pardigon N, Reynes JM, Pettinelli F, Biscornet L, Diancourt L, Michel S, Duquerroy S, Guigon G, Frenkiel MP, Brehin AC, Cubito N, Despres P, Kunst F, Rey FA, Zeller H, Brisse S, 2006. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 3: e263.
-
7.
International Society for Infectious Diseases, 2010. CHIKUNGUNYA, (04): MADAGASCAR (FIANARANTSOA). Archive number 2010026.0639. Available at: http://www.promedmail.org. Accessed September 25, 2012.
-
8.
Kularatne SA, Gihan MC, Weerasinghe SC, Gunasena S, 2009. Concurrent outbreaks of chikungunya and dengue fever in Kandy, Sri Lanka, 2006–07: a comparative analysis of clinical and laboratory features. Postgrad Med J 85: 342–346.
-
9.
Yoosuf AA, Shiham I, Mohamed AJ, Ali G, Luna JM, Pandav R, Gongal GN, Nisaluk A, Jarman RG, Gibbons RV, 2009. First report of chikungunya from the Maldives. Trans R Soc Trop Med Hyg 103: 192–196.
-
10.
Sam IC, Chan YF, Chan SY, Loong SK, Chin HK, Hooi PS, Ganeswrie R, Abubakar S, 2009. Chikungunya virus of Asian and Central/East African genotypes in Malaysia. J Clin Virol 46: 180–183.
-
11.
AbuBakar S, Sam IC, Wong PF, MatRahim N, Hooi PS, Roslan N, 2007. Reemergence of endemic chikungunya, Malaysia. Emerg Infect Dis 13: 147–149.
-
12.
Ng LC, Tan LK, Tan CH, Tan SS, Hapuarachchi HC, Pok KY, Lai YL, Lam-Phua SG, Bucht G, Lin RT, Leo YS, Tan BH, Han HK, Ooi PL, James L, Khoo SP, 2009. Entomologic and virologic investigation of chikungunya, Singapore. Emerg Infect Dis 15: 1243–1249.
-
13.
Rianthavorn P, Prianantathavorn K, Wuttirattanakowit N, Theamboonlers A, Poovorawan Y, 2010. An outbreak of chikungunya in southern Thailand from 2008 to 2009 caused by African strains with A226V mutation. Int J Infect Dis 14 (Suppl 3): e161–e165.
-
14.
Yergolkar PN, Tandale BV, Arankalle VA, Sathe PS, Sudeep AB, Gandhe SS, Gokhle MD, Jacob GP, Hundekar SL, Mishra AC, 2006. Chikungunya outbreaks caused by African genotype, India. Emerg Infect Dis 12: 1580–1583.
-
15.
International Society for Infectious Diseases, 2010. CHIKUNGUNYA, (30) CHINA (GUANGDONG), REUNION. Archive number 20101008.3661. Available at: http://www.promedmail.org. Accessed September 25, 2012.
-
16.
Angelini R, Finarelli AC, Angelini P, Po C, Petropulacos K, Silvi G, Macini P, Fortuna C, Venturi G, Magurano F, Fiorentini C, Marchi A, Benedetti E, Bucci P, Boros S, Romi R, Majori G, Ciufolini MG, Nicoletti L, Rezza G, Cassone A, 2007. Chikungunya in north-eastern Italy: a summing up of the outbreak. Euro Surveill 12: E071122.2.
-
17.
Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, Cordioli P, Fortuna C, Boros S, Magurano F, Silvi G, Angelini P, Dottori M, Ciufolini MG, Majori GC, Cassone A, 2007. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370: 1840–1846.
-
18.
Grandadam M, Caro V, Plumet S, Thiberge JM, Souares Y, Failloux AB, Tolou HJ, Budelot M, Cosserat D, Leparc-Goffart I, Despres P, 2011. Chikungunya virus, southeastern France. Emerg Infect Dis 17: 910–913.
-
19.
Schwartz O, Albert ML, 2010. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol 8: 491–500.
-
20.
Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV, 2008. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg Infect Dis 14: 412–415.
-
21.
Casolari S, Briganti E, Zanotti M, Zauli T, Nicoletti L, Magurano F, Fortuna C, Fiorentini C, Grazia Ciufolini M, Rezza G, 2008. A fatal case of encephalitis associated with chikungunya virus infection. Scand J Infect Dis 40: 995–996.
-
22.
Ganesan K, Diwan A, Shankar SK, Desai SB, Sainani GS, Katrak SM, 2008. Chikungunya encephalomyeloradiculitis: report of 2 cases with neuroimaging and 1 case with autopsy findings. AJNR Am J Neuroradiol 29: 1636–1637.
-
23.
Josseran L, Paquet C, Zehgnoun A, Caillere N, Le Tertre A, Solet JL, Ledrans M, 2006. Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 12: 1994–1995.
-
24.
Ramchurn SK, Goorah SS, Makhan M, Moheeput K, 2008. Excess mortality as an epidemic intelligence tool in chikungunya mapping. Euro Surveill 13: 8039.
-
25.
Tandale BV, Sathe PS, Arankalle VA, Wadia RS, Kulkarni R, Shah SV, Shah SK, Sheth JK, Sudeep AB, Tripathy AS, Mishra AC, 2009. Systemic involvements and fatalities during chikungunya epidemic in India, 2006. J Clin Virol 46: 145–149.
-
26.
Powers AM, Logue CH, 2007. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 88: 2363–2377.
-
27.
Jupp PG, McIntosh BM, 1988. Chikungunya virus disease. Monath TP, ed. The Arboviruses: Epidemiology and Ecology. Boca Raton, FL: CRC Press, 137–157.
-
28.
Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S, 2007. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 3: e201.
-
29.
Tsetsarkin KA, Chen R, Leal G, Forrester N, Higgs S, Huang J, Weaver SC, 2011. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc Natl Acad Sci USA 108: 7872–7877.
-
30.
Benedict MQ, Levine RS, Hawley WA, Lounibos LP, 2007. Spread of the tiger: global risk of invasion by the mosquito Aedes albopictus. Vector Borne Zoonotic Dis 7: 76–85.
-
31.
Liumbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C, Macini P, Tomasini I, Zucchelli P, Silvestri AR, Sambri V, Pupella S, Catalano L, Piccinini V, Calizzani G, Grazzini G, 2008. The chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 6: 199–210.
-
32.
Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP, 2009. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de La Reunion. Transfusion 49: 1083–1091.
-
33.
Brouard C, Bernillon P, Quatresous I, Pillonel J, Assal A, De Valk H, Desenclos JC, 2008. Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 48: 1333–1341.
-
34.
Sissoko D, Moendandze A, Malvy D, Giry C, Ezzedine K, Solet JL, Pierre V, 2008. Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005–2006: a population-based survey. PLoS ONE 3: e3066.
-
35.
Queyriaux B, Simon F, Grandadam M, Michel R, Tolou H, Boutin JP, 2008. Clinical burden of chikungunya virus infection. Lancet Infect Dis 8: 2–3.
-
36.
Appassakij H, Khuntikij P, Kemapunmanus M, Wutthanarungsan R, Silpapojakul K, 2012. Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? Transfusion 26: [Epub ahead of print], doi:10.1111/j.1537-2995.2012.03960.x.
-
37.
Gerardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, Michault A, de Lamballerie X, Flahault A, Favier F, 2008. Estimating chikungunya prevalence in La Reunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC Infect Dis 8: 99.
-
38.
Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L, 2005. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 45: 580–590.
-
39.
Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K, 2003. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 47: 475–479.
-
40.
Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, Corash L, 2006. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46: 1168–1177.
-
41.
Lin L, Dikeman R, Molini B, Lukehart S, Lane R, Dupuis K, Metzel P, Corash L, 2004. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 44: 1496–1504.
-
42.
Grellier P, Benach J, Labaied M, Cahrneau S, Gil H, Monsalve G, Alfonso R, Sawyer L, Lin L, Steiert M, Dupuis K, 2008. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 48: 1676–1684.
-
43.
Sawyer L, Hanson D, Castro G, Luckett W, Dubensky TW, Stassinopoulos A, 2007. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 47: 1062–1070.
-
44.
Grass JA, Hei DJ, Metchette K, Cimino GD, Weisenhahn GP, Corash L, Lin L, 1998. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 91: 2180.
-
45.
Eastman RT, Barrett LK, Dupuis K, Buckner FS, Van Voorhis WC, 2005. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 45: 1459–1463.
-
46.
Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman J, Isaacs ST, Wollowitz S, Corash L, 1997. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37: 423–435.
-
47.
Wollowitz S, 2001. Fundamentals of the psoralen-based helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 38 (Suppl 11): 4–11.
-
48.
Irsch J, Pinkoski L, Corash L, Lin L, 2010. INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis. Vox Sang 98: 47–55.
-
49.
Lin L, Alfonso R, Behrman B, Corten L, Damonte PB, Dikeman R, Dupuis K, Hei D, Lin CY, Londe HF, Metchette K, Phan T, Reames AA, Rheinschmidt M, Savoor A, Tessman J, Corash L, 1998. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Infusther Tranfsusmed 25: 39–48.
-
50.
McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard FT, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG, 2004. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 104: 1534–1541.
-
51.
de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L, 2005. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 45: 1362–1372.
-
52.
van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L, 2003. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 101: 2426–2433.
-
53.
Lin L, Conlan MG, Tessman J, Cimino G, Porter S, 2005. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 45: 1610–1620.
-
54.
ANSM, 2013. French Agency for the Safety of Health Products. France Annual Haemovigilance report 2009. Available at: http://www.ansm.sante.fr/Mediatheque/Publications/Information-in-English. Accessed September 20, 2012.
-
55.
Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, Raidot JP, Kandel G, Wiesel ML, Corash L, 2011. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 51: 622–629.
-
56.
Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L, 2008. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 94: 315–323.
-
57.
Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L, 2009. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 49: 1412–1422.
-
58.
Devine DV, Sher GD, Reesink HW, Panzer S, Hetzel PA, Wong JK, Horvath M, Leitner GC, Schennach H, Nussbaumer W, Genoe K, Cioffi JM, Givisiez FN, Rogerson M, Howe D, Delage G, Sarappa C, Charbonneau, Fu Y, Sarlija D, Vuk T, Strauss Patko M, Balija M, Jukic I, Ali A, Auvinen MK, Jaakonsalo E, Cazenave JP, Waller C, Kientz D, David B, Walther-Wenke G, Heiden M, Lin CK, Tsoi WC, Lee CK, Barotine-Toth K, Sawant RB, Murphy W, Quirke B, Bowler P, Shinar E, Yahalom V, Aprili G, Piccoli P, Gandini G, Tadokaro K, Nadarajan VS, de Kort W, Jansen N, Flanagan P, Forsberg PO, Hervig T, Letowska M, Lachert E, Dudziak K, Antoniewicz-Papis J, de Olim G, Nascimento F, Hindawi S, Teo D, Reddy R, Scholtz J, Swanevelder R, Rovira LP, Sauleda S, Carasa MA, Vaquero MP, Ania MA, Gulliksson H, Holdsworth S, Cotton S, Howell C, Baldwin C, Cusick RM, Geele GA, Paden C, McEvoy P, Gottschall JL, McLaughlin LS, Benjamin RJ, Eder A, Draper NL, AuBuchon JP, Leon de Gonzalez G, 2010. Inventory management. Vox Sang 98: e295–e363.
-
59.
Reed LJ, Muench H, 1938. A simple method for estimating fifty per cent endpoints. Am J Hyg 27: 493–497.
-
60.
Vanlandingham DL, Keil SD, McElroy Horne K, Pyles R, Goodrich RP, Higgs S, 2012. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 53: 284–290.
-
61.
Leo YS, Chow ALP, Tan LK, Lye DC, Lin L, Ng LC, 2009. Chikungunya outbreak, Singapore 2008. Emerg Infect Dis 15: 836–837.
-
62.
Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Schwartz O, 2007. Characterization of reemerging chikungunya virus. PLoS Pathog 3: e89.
-
63.
McIntosh BM, Paterson HE, Donaldson JM, de Sousa J, 1963. Chikungunya virus: viral susceptibility and transmission studies with some vertebrates. S Afr J Med Sci 28: 45.
-
64.
Chemsky MA, Larke RP, 1977. Contrasting effects of rabbit and human platelets on chikungunya virus infectivity. Can J Microbiol 23: 1237–1244.
-
65.
Larke RP, Wheelock EF, 1970. Stabilization of chikungunya virus infectivity by human blood platelets. J Infect Dis 122: 523–531.
-
66.
Parola P, de Lamballerie X, Jourdan J, Rovery C, Vaillant V, Minodier P, Brouqui P, Flahault A, Raoult D, Charrel RN, 2006. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 12: 1493–1499.
-
67.
Carletti F, Bordi L, Chiappini R, Ippolito G, Sciarrone MR, Capobianchi MR, Di Caro A, Castilletti C, 2007. Rapid detection and quantification of chikungunya virus by a one-step reverse transcription polymerase chain reaction real-time assay. Am J Trop Med Hyg 77: 521–524.
-
68.
Tomson B, Brand A, 2010. In vivo tracking of transfused platelets for recovery and survival studies: an appraisal of labeling methods. Transfus Apheresis Sci 42: 53–61.
-
69.
Custer B, Agapova M, Martinez RH, 2010. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 50: 2461–2473.
-
70.
INTERCEPT In Use, 2012. Intercept Blood System. Available at: www.interceptbloodsystem.com/intercept-in-use/overview.html. Accessed December 15, 2012.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 608 | 488 | 33 |
| Full Text Views | 657 | 5 | 0 |
| PDF Downloads | 77 | 10 | 0 |